MedTrace Logo

PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC

NCT07043907 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 115

Last updated 2025-07-01

No results posted yet for this study

Summary

A Single-center, Single-arm Clinical Trial on the Safety and Efficacy of PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Stage IIIA Non-Small Cell Lung Cancer

Conditions

  • Stage IIIA Non-small Cell Lung Cancer

Interventions

DRUG

PANK-003 cell injection combined with standard postoperative adjuvant chemotherapy

PANK-003 cell injection combined with standard postoperative adjuvant chemotherapy

Sponsors & Collaborators

  • Shenzhen Celconta Life Science Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-08
Primary Completion
2028-07-08
Completion
2029-06-18

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07043907 on ClinicalTrials.gov